We have a diverse pipeline of multi-targeted therapies in development for both autoimmune/inflammatory disease and oncology.
Conditional CD28 Costimulator and Dual PD-L1/CTLA-4 Inhibitor
Monotherapy, Advanced Malignancies
KEYTRUDA® Combination Advanced Malignancies
Davoceticept (ALPN-202) is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer.
We are currently enrolling NEON-1, a Phase 1 dose escalation and expansion study of davoceticept in patients with advanced malignancies (NCT04186637) and NEON-2, a Phase 1 combination study of davoceticept with KEYTRUDA® (pembrolizumab) in patients with advanced malignancies (NCT04920383).
Dual B Cell Cytokine (BAFF/APRIL) Antagonist
SLE and other B cell-mediated diseases
ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases.
We reported data from the ongoing RUBY-1 study, a Phase 1 study of ALPN-303 in healthy volunteers (NCT05034484) in September 2022. This study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALPN-303.
Dual CD28/ICOS Antagonist
Systemic lupus erythematosus
Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.
We are currently enrolling Synergy, a Phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.
Next Generation TCR T-cell Therapies